Skip to main content

Table 3 Characteristics of patients experiencing serious bleeding events

From: Drotrecogin alfa (activated): real-life use and outcomes for the UK

Characteristics Admissions experiencing serious bleeding events (n = 80)
Site of serious bleeding event (n [%])
   Gastrointestinal 29 (33.7)
   Skin or soft tissue 19 (22.1)
   Intra-abdominal 9 (10.5)
   Intracranial 7 (8.1)
   Intrathoracic 5 (5.8)
   Genitourinary 3 (3.5)
   Retroperitoneal 0 (0.0)
   Other (source identified)a 6 (7.0)
   Other (source unidentified) 5 (5.8)
Age (years; mean ± SD) 58.5 (14.9)
APACHE II score (mean ± SD)
   Acute physiology score 19.6 (7.5)
   Score 22.9 (7.6)
ICNARC model physiology score (mean ± SD) 30.5 (8.3)
Serious conditions in past medical historyb (n [%])
   Liver 1 (1.3)
   Cardiovascular 0 (0.0)
   Respiratory 0 (0.0)
   Renal 1 (1.3)
   Immunosuppressed 4 (5.0)
Admission typec (n [%])
   Medical 55 (68.8)
   Elective surgical 3 (3.8)
   Emergency surgical 22 (27.5)
Organ systems failing during first 24 hours of stay in critical care (n [%])
   Cardiovascular 79 (98.8)
   Respiratory 72 (90.0)
   Renal 32 (40.5)
   Haematological 28 (35.0)
   Metabolic acidosis 68 (85.0)
Number of organ systems failing during first 24 hours of stay in critical care (n [%])
   <2 1 (1.3)
   2 5 (6.3)
   3 38 (47.5)
   4 26 (32.5)
   5 10 (12.5)
Primary site of infectiond (n [%])
   Lung 20 (27.0)
   Abdomen 33 (44.6)
   Urinary tract 5 (6.8)
   Other 16 (21.6)
Positive blood culturee (n [%]) 26 (36.1)
Organisms cultured (n [%])
   Any 52 (65.8)
   Gram-negative 22 (42.3)
   Gram-positive 26 (50.0)
   Fungus 12 (23.1)
Mortality (n [%])
   Unit 31 (3 8.8)
   Hospitalf 39 (48.8)
Location at 28 days (n [%])
   Died 30 (37.5)
   Unit 22 (27.5)
   Hospital 22 (27.5)
   Out of Hospitalf 6 (7.5)
Unit length of stay (days; median [IQR])
   Unit survivors 20.7 (12.7–28.5)
   Unit non-survivors 9.8 (5.9–23.9)
Hospitalg length of stay (days; median [IQR])
   Hospital survivors 60 (43–105)
   Hospital nonsurvivors 19 (8–32)
  1. aOther (source identified) was four from the oral/nasal cavity and two from the lungs/trachea. bEvidence defined as follows, during prior 6 months (except those terms highlighted with asterisk, which are not restricted to the preceding 6 months): liver (biopsy proven cirrhosis, portal hypertension, hepatic encephalopathy); cardiovascular (very severe cardiovascular disease [New York Heart Association functional classification IV]); respiratory (severe respiratory disease [shortness of breath with light activity, for example walking 20 m on level ground], home ventilation); renal (chronic renal replacement therapy for irreversible renal disease); immunosuppressed (AIDS*, steroid treatment [daily], radiotherapy, chemotherapy, metastatic disease, acute myelogenous/lymphocytic leukaemia or multiple myeloma, chronic myelogenous/lymphocytic leukaemia, lymphoma, congenital immunohumoral or cellular immune deficiency state*). cSurgical admissions are defined as those admitted directly to the unit from theatre and recovery. dPrimary site of infection was not reported for six (7.5%) admissions. eA blood culture was reported as not done for six (7.5%) admissions. fDischarged alive from acute hospital at or before 28 days. gExcluding readmissions within the same hospital stay. APACHE, Acute Physiology and Chronic Health Evaluation; ICNARC, Intensive Care National Audit & Research Centre; IQR, interquartile range; SD, standard deviation.